There are already drugs, including anti-migraine targeting the CGRP pathway (i.e., anti-CGRP Monoclonal Antibodies and Gepants) in the market that could be candidates that effect upstream or downstream CGRP-related pathway effects on the evolution of SAND (Khan et al., 2019; Dodick et al., 2023; Haanes and Edvinsson, 2023; Reuter, 2023). The gene discussed is CALCA; the disease is migraine disorder.